Research programme: ion channel modulators - Cadent Therapeutics/Saniona

Drug Profile

Research programme: ion channel modulators - Cadent Therapeutics/Saniona

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aniona
  • Developer Cadent Therapeutics; Saniona
  • Class Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Small conductance calcium-activated potassium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Ataxia; Essential tremor

Most Recent Events

  • 03 Nov 2017 Preclinical trials in Essential tremor in USA before November 2017 (Candent Therapeutics pipeline, November 2017)
  • 17 Oct 2017 Luc Therapeutics is now called Cadent Therapeutics
  • 14 Aug 2017 Cadent Therapeutics plans phase I clinical trials for Ataxia in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top